Biogen has made no secret of its aspirations in gene therapy, setting up a dedicated business unit for the category in 2014 and following that with a $1 billion alliance with Applied Genetic ...
Hosted on MSN13d
FDA & EMA Accept Biogen's Filings for Higher Dose SMA DrugBiogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...
Pharmaceutical Technology on MSN9d
Sage rejects Biogen’s $469m takeover bidSage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
Hosted on MSN22d
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report SaysFDA Says Biogen Abandons Alzheimer Drug Aduhelm After Years of Tumult Unproven Drugs Reap Billions for Years After Taking FDA Shortcut Sarepta’s Gene Therapy Benefits Are Unclear, FDA Staff Says ...
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after receiving an “unsolicited” buyout offer. Biogen and Sage originally joined ...
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Biogen expects revenue from new launches to ... 2025 Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves ...
GlobalData on MSN9d
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback